checkAd
    Startseite > Aktien > Precision BioSciences > Nachrichten
    Precision BioSciences Aktie
    12,840
     
    USD
    +3,55 %
    +0,440 USD
    Letzter Kurs 02:00:00 Nasdaq
    12,680
     
    USD
    100 STK
    Geldkurs 20.05.24
    12,850
     
    USD
    200 STK
    Briefkurs 20.05.24
    ISIN: US74019P2074 · WKN: A400AS · SYM: DTIL · USA

    Neueste Nachrichten

    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    17.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
    13.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
    08.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences to Report First Quarter Results on May 13, 2024
    07.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
    07.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
    01.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
    16.04.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
    27.03.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
    20.03.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
    19.03.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
    06.03.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
    01.03.24 · Business Wire (engl.) · Precision BioSciences